wuxi biologics

Gene sequencing company raises $200m

With the debate about gene-edited babies raging, it is a sensitive time for Wuxi NextCODE to announce the completion of Series C funding.

November 29, 2018

Volatility takes shine off golden age for Asian follow-ons

Follow-on activity is starting to pick up across Asia, but volatility is making after-market performance difficult to judge for buyers and sellers alike.

April 05, 2018

Wuxi AppTec joins biologics IPO rush

Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.

May 25, 2017

Wuxi Biologics readies Hong Kong relisting

Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.

January 06, 2017